| Field | Specification |
|---|---|
| Mfr No | |
| Endotoxin Level | |
| Form | Liquid |
| Product Type | |
| Purity | |
| Storage | |
| Target | |
| UniProt # |
Scientific Background
Granulocyte colony-stimulating factor (CSF3R) is a ~22 kDa protein. Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes.
Product Description
Efbemalenograstim Alfa (HY258036) is a research-grade recombinant antibody targeting C17orf33. Highlights- Research Grade — For PK/PD studies, assay development, and ADA research.
Protein Specifications
| Target | C17orf33, CSF3, Filgrastim, G-CSF, GCSF, Granulocyte colony-stimulating factor, Lenograstim, Pluripoietin |
|---|---|
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| UniProt | P09919 |
| Endotoxin Level | < 10 EU/mg |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Applications
| Application |
|---|
| Functional Assay |
Safety & Handling
Customization & Add-ons: Can't find the protein you need—or require a custom format for your assay? We can help you source the best match or support custom recombinant protein solutions for diverse research needs, including expression system selection, tag and fusion options (His, Fc, biotin), purification grade options, formulation preferences (buffer selection, carrier-free, lyophilized or liquid), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
